Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases

World Journal of Gastroenterology

Volumn 17, Issue 39, 2011, Pages 4440-4444

  Nishimura, Takeshi ^a   Furihata, Makoto ^a   Kubo, Hideyuki ^a   Tani, Masao ^a   Agawa, Senichiro ^a   Setoyama, Ryuhei ^a   Toyoda, Tomikatsu ^b  

^a Department of Surgery   (Japan)

^b TOKYO KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

Anti vascular endothelial growth factor therapy; Bevacizumab; Central nervous system; Colorectal cancer; Intracranial hemorrhage

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; COLON CARCINOMA; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CRANIOTOMY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSARTHRIA; HEMICOLECTOMY; HUMAN; LABORATORY TEST; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; PARTIAL HEPATECTOMY; RECTUM ABDOMINOPERINEAL RESECTION; RECTUM CARCINOMA; THROMBOCYTOPENIA;

EID: 81755162307     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i39.4440     Document Type: Article

References (24)

1. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP. Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010; 16: 269-278
2. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676
3. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005; 333: 328-335
4. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005; 10: 382-391
5. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracar-da S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double- blind phase III trial. Lancet 2007; 370: 2103-2111
6. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffng S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fuorouracil, and leucovo- rin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
7. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Ne-munaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and pacli- taxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191
8. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dow-lati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550
9. Gordon MS, Margolin K, Talpaz M, Sledge GW, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-850
10. Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 2008; 10: 624-630
11. Bhaskara A, Eng C. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metas-tases. Clin Colorectal Cancer 2008; 7: 65-68
12. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Ne-munaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and pacli-taxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22: 2184-2191
13. Nguyen TD, Abrey LE. Intracranial hemorrhage in patients treated with bevacizumab and low-molecular weight heparin. Clin Adv Hematol Oncol 2007; 5: 375-376; discussion 377-379
14. Tanvetyanon T, Murtagh R, Bepler G. Rupture of a cerebral arteriovenous malformation in a patient treated with beva-cizumab. J Thorac Oncol 2009; 4: 268-269
15. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Gro-chow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24: 3354-3360
16. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB. Bevacizumab in combination with oxaliplatin, fuorouracil, and leucovo- rin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
17. Socinski MA, Langer CJ, Huang JE, Kolb MM, Compton P, Wang L, Akerley W. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009; 27: 5255-5261
18. Archer V, Reck M, Sandler AB, Johnsion DH, Kong G, Strickland DK, Bennouna J. Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. J Clin Oncol 2008; 26: abstract 8114
19. Morgensztern D, Govindan R. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology. Clin Lung Cancer 2008; 9 Suppl 2: S57-S61
20. Oh Y, Stewart DJ. Systemic therapy for lung cancer brain metastases: a rationale for clinical trials. Oncology (Williston Park) 2008; 22: 168-178; discussion 178, 183, 188 passim
21. Labidi SI, Bachelot T, Ray-Coquard I, Mosbah K, Treilleux I, Fayette J, Favier B, Galy G, Blay JY, Guastalla JP. Bevaci-zumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 2009; 9: 118-121
22. Saranadasa M, Wang ES. Vascular endothelial growth factor inhibition: conflicting roles in tumor growth. Cytokine 2011; 53: 115-129
23. Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Guru-rangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007; 13: 1253-1259
24. Giles F, Rizzieri D, Karp J, Vey N, Ravandi F, Faderl S, Khan KD, Verhoef G, Wijermans P, Advani A, Roboz G, Kantarjian H, Bilgrami SF, Ferrant A, Daenen SM, Karsten V, Cahill A, Albitar M, Mufti G, O'Brien S. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007; 25: 25-31